Learn more about the exciting field of intratumoral immunotherapy and OncoSec’s role as a key leader in this emerging space.
Watch the Video
OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab
OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City
OncoSec Announces Positive Phase II Data Demonstrating Company’s ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients
Our core technology platform continues to advance through clinical trials for various cancers.
The ImmunoPulse® platform is designed to boost the immune system to recognize and attack tumors.
OncoSec continues to establish relationships with industry leaders to further advance our research.
PDF | 2.0 MB
PDF | 1.0 MB